Genus Life Sciences Patent-Cliff Exposure & CMS Drug Spending Portfolio

Genus Life Sciences (US): 3 reconciled FDA prescription therapies, $342.6M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies3
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2038-01-01
2024 CMS Total Public Spend$342.6M
2024 Medicare Part D Spend$290.9M
2024 Medicaid Spend$51.7M
California HCAI SB 17 Filings4 WAC filings (max 44.8% 2-yr change)